Gilad Thaler

Expedited approvals for new cancer drugs have led to massive revenue increases for pharmaceutical companies. However, a large number of these treatments aren't proven to extend the lives of patients very long, if at all. Meanwhile, drugs that do work are sometimes prescribed in far higher volumes than necessary, increasing Big Pharma's bottom line.

Producer / DP